At a glance
ClinicalIndex Comparison RecordN/ACompleted· 20 enrolled
Drug / intervention
Prazosin +1 moredrug
Likely dose
Prazosin 4 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Prazosin Treatment for Disruptive Agitation in Alzheimer's Disease
Seattle Institute for Biomedical and Clinical Research·interventional·Posted May 19, 2010·Updated May 21, 2015
In Brief
A clinical study evaluating Prazosin and Placebo for Alzheimer's Disease. Completed, enrolled 20 participants across 1 site.
Detailed Summary
A study of outpatient participants with Alzheimer's disease or a related dementia who have difficult behaviors that are upsetting for them or their caregivers. Prazosin is a medication that is commonly used to treat people with high blood pressure. Research with prazosin has shown that it may be effective in treating behavioral problems by reducing excess adrenalin effects in the brain.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAlzheimer's Disease
CountriesUnited States
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2010
First PostedMay 2010
Primary CompletionMar 2014
TodayJul 2026
First PostedMay 19, 2010
Enrollment StartMar 1, 2010
Primary CompletionMar 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4 yearsPosted 16.1 years ago
Interventions
Prazosindrug
4 mg capsules twice daily for 12 weeks
Placebodrug
Placebo capsules twice daily for 12 weeks